Physician profile
Laura Record
NPI 1194965921
$3,085.35
in general payments reported to CMS, 2019-2025
27 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $240 · 2023: $988 · 2024: $608 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.21 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $732.56 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $578.07 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.24 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Abbvie INC. | $203.27 | 2021 | |
| Grifols USA, LLC | $155.55 | 2022-2024 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $140.14 | 2021-2025 | Nuzyra |
| Amgen INC. | $130.11 | 2023-2024 | Tezspire |
| Insmed, INC. | $106.06 | 2025 | Arikayce |
| Pfizer INC. | $105.18 | 2021-2025 | |
| Mylan Specialty L.P. | $73.20 | 2023-2024 | Yupelri |
| Upsher-Smith Laboratories LLC | $57.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.57 | 2021 | |
| Lilly USA, LLC | $56.18 | 2021 | |
| Merck Sharp & Dohme LLC | $55.87 | 2023-2025 | Winrevair, Recarbrio, Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $48.09 | 2023 | Glassia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $44.30 | 2022-2025 | Uptravi, Opsynvi |
| Amarin Pharma, INC. | $40.45 | 2021 | |
| Breas Medical, INC. | $25.77 | 2022 | |
| Phadia US INC. | $24.73 | 2024 | Immunocap |
| Allergan, INC. | $22.79 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.63 | 2021 | |
| Baxter Healthcare | $18.31 | 2023 | Hillrom - Life 2000 Ventilation System |
| Biohaven Pharmaceuticals, INC. | $17.67 | 2021 | |
| Shionogi INC | $17.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.02 | 2021 | |
| Viiv Healthcare Company | $16.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.54 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Record listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.